# OnCo record hepatocellular-carcinoma-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/hepatocellular-carcinoma-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "hepatocellular-carcinoma-signalling" ;
  schema:name "Hepatocellular carcinoma (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05225"@en, "Hepatocellular carcinoma"@en ;
  schema:description "This KEGG map shows how hepatitis viruses, alcohol and aflatoxin leave the liver with mutations in telomerase, TP53, Wnt/beta-catenin, PI3K/AKT/mTOR and the oxidative stress sensor NRF2, which together drive liver cancer. It matters because the map explains why liver cancer is treated mainly with angiogenesis blockers and immunotherapy rather than a single targeted drug."@en ;
  schema:url <https://onco.cc/pathways/hepatocellular-carcinoma-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05225>, <https://doi.org/10.1038/s41572-020-00240-3> ;
  onco:related <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/keap1-nrf2/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/proteoglycans-in-cancer/> ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/mtor/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/gpc3/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/rivoceranib/>, <https://onco.cc/drugs/donafenib/> ;
  onco:pathways <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/keap1-nrf2/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-llovet-nat-rev-dis-primers/> .